<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20100910130604+02'00'</creation_date><modification_date>D:20100910130606+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-285_h_dec_10.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header></section><section><header>en  
   en</header><p>european commission brussels, 6.9.2010 c(2010)6239</p></section><section><header>commission decision of 6.9.2010 
 amending the marketing authorisation granted by decision c(2004)3653 for 
 “apidra - insulin glulisine”, a medicinal product for human use</header><p>(only the german text is authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission decision of 6.9.2010 
 amending the marketing authorisation granted by decision c(2004)3653 for 
 “apidra - insulin glulisine”, a medicinal product for human use 
 (text with eea relevance)</header><p>the european commission, having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 17(2) thereof, 
 having regard to the notification submitted by sanofi-aventis deutschland gmbh, under 
 the first and the second subparagraph of article 14(1) of regulation (ec) no 1234/2008, 
 whereas: 
 (1)</p><p>the european medicines agency has informed the marketing authorisation 
 holder and the commission of its favourable opinion on the minor variations of 
 type ia, notified between 31 march 2010 and 29 july 2010, and of the need to 
 amend the decision granting the marketing authorisation. 
 (2)</p><p>the marketing authorisation should be updated and decision c(2004)3653 of 27 
 september 2004 should therefore be amended accordingly. the community 
 register of medicinal products should also be updated. 
 (3)</p><p>for the sake of clarity and transparency, it is appropriate, following the 
 amendment of part or parts of the annexes, to provide for a consolidated version 
 thereof. the annexes to decision c(2004)3653 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(2004)3653 is amended as follows:</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>1) the following notifications for minor variations are added to the marketing authorisation: 
 application number 
 scope (eu numbers affected) 
 emea/h/c/557/ia/4g 
 c.i.9.a), 
 c.i.9.b), 
 c.i.9.c), 
 c.i.9.d), 
 c.i.9.h) 
 (eu/1/04/285/001-036)</p><p>
 2) annex ii is replaced by the text set out in the annex ii to this decision. 
 article 2 this decision is addressed to sanofi-aventis deutschland gmbh, d-65926 frankfurt am main, deutschland. 
 done at brussels, on 6.9.2010.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>